Michelle A. Lee, MD, PhD
- Practice Specialty
- Pediatrics, Pediatrics - Hematology-Oncology (Cancer)
- Medical Education
- Harvard Medical School
- Childrens Hospital of Philadelphia
- Boston Children's Hospital
- Main Location
- Academic Title
- Assistant Professor of Pediatrics, Albert Einstein College of Medicine
- Administrative Title
- Director of the Transplantation and Cellular Therapy Program
- Clinical Focus
- Dr. Lee’s clinical focus is on using bone marrow transplantation to cure patients of sickle cell disease. Sickle cell disease can be cured with transplantation from a sibling who is matched at HLA genes. Unfortunately, most persons with sickle cell disease don’t have such an HLA-matched sibling. Also, transplantation from an alternative donor is not yet as successful. Dr. Lee’s goal is for all persons with sickle cell disease to know what transplant options are available to them. She is invested in building a program that can offer transplantation to persons with sickle cell disease whatever their disease complications and donor situations.
- Research Focus
- Dr. Lee aims to understand factors that impact transplant outcomes, especially those that may be related to race and ethnicity. She is developing a research study that will allow investigation of biological and social mechanisms that may be important in determining how patients recover. It is her hope that knowledge gained will eventually be applied to make transplants safer for all.
Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.
Amyloid Precursor Protein Is Associated with Aggressive Behavior in Nonluminal Breast Cancers.
Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast.
Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.
Passenger deletions generate therapeutic vulnerabilities in cancer.
Mig-6 controls EGFR trafficking and suppresses gliomagenesis.
Thomas J. Watson Foundation, experiential fellowship to investigate “Traditional medicine and women’s (8/92 – 8/93)
Ivy Oration Class Day Speaker, Spelman College, highest GPA (1992)
James Tolbert Shipley Prize, Harvard Medical School (2003)
Hall of Honor, 27th Annual Enshrinement, Fairborn City Schools, Ohio (2014)
Michelle A. Lee, MD, PhD, is an Attending Physician in the Division of Hematology, Oncology, and Marrow & Blood Cell Transplantation at Childrens Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at Albert Einstein College of Medicine. Dr. Lees clinical focus is on using bone marrow transplantation to cure patients of sickle cell disease. Her goal is for all persons with sickle cell disease to know what transplant options are available to them. Dr. Lee is currently working on building a program that can offer transplantation to persons with sickle cell disease whatever their disease complications and donor situations.
Dr. Lee attended Spelman College in Atlanta, Georgia, where she received her Bachelor of Science degree in Biology. From 1993 to 2003, Dr. Lee attended Harvard Medical School in Boston where she earned her Doctorate of Medicine degree. During that time, she also earned her Doctor of Philosophy degree in the Department of Cell and Developmental Biology at Harvard Graduate School. Dr. Lee completed internship and residency in General Pediatrics at The Childrens Hospital of Philadelphia. She then completed a fellowship in Pediatric Hematology/Oncology at Dana-Farber Cancer Institute/Boston Childrens Hospital.
Dr. Lees research aims to understand factors that impact transplant outcomes, especially those that may be related to race and ethnicity. She is currently developing a research study that will allow investigation of biological and social mechanisms that may be important in determining how patients recover from transplant. She hopes that the knowledge gained from this study will eventually be applied to make transplants safer for all patients. Dr. Lees research has been published in various reviewed journals, books, chapters within books and review articles. She has been an invited speaker for presentations nationally on numerous topics, including hematopoietic stem cell transplantation in sickle cell disease and gene therapy in sickle cell disease.
Dr. Lee is board certified in Pediatric Hematology-Oncology by the American Board of Pediatrics. She is a member of the American Society of Blood and Marrow Transplantation, among other organizations.